Upstream Bio, Inc.

Stage 4 · Declining · week 6

As of Oct 22, 2026, Upstream Bio is in Stage 4, the downtrend phase, now in week 6 (since Sep 15, 2026). It closed at $2.99, 90.8% below its 52-week high and below its 200-day average, which is falling.

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. More about the company

$2.99

+6.79% today

$164M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is UPB early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2024-10-11 → 2026-10-22

S? 42w

S2 26w

S4 9w

S4 14w

2024-10-112026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S? 42w → S1 2w → S2 26w → S3 4w → S4 9w → S1 2w → S4 14w → S1 1w → S4 5w current

Total tracked: 106 weeks across 9 stage runs.

UPB among Biotechnology505th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…505	UPBUpstream Bio, Inc.	Stage 4 · wk 6	8	−42.4%

vs 52W High

-90.8%

$2.76 lo$32.60 hi

90.8% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 6

1w13w26w

Week 6, early Stage 4 decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-70.4%

200 DMA: $10.09 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

1.77x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-42.4%

-53.4%

-68.9%

YTD

-89.0%

-86.6%

Scan Membership

Not in any current scan.

Recent Stage Timeline

2026-10-22S4

Wk 6 · Vol 1.77x

2026-10-21S4

Wk 6 · Vol 1.57x

2026-10-20S4

Wk 6 · Vol 2.12x

2026-10-19S4

Wk 5 · Vol 2.08x

2026-10-16S4

Wk 5 · Vol 2.47x

2026-10-15S4

Wk 5 · Vol 1.75x

2026-10-14S4

Wk 5 · Vol 2.15x

2026-10-13S4

Wk 5 · Vol 1.43x

2026-10-12S4

Wk 4 · Vol 1.19x

2026-10-09S4

Wk 4 · Vol 1.70x

2026-10-08S4

Wk 4 · Vol 4.37x

2026-10-07S4

Wk 4 · Vol 1.41x

Moving averages & range

50 DMA

$5.41

200 DMA

$10.09

52W High

$32.60

52W Low

$2.76

5D Low

$2.76

Resistance levels (recent highs)

20d High

$5.36

60d High

$7.52

120d High

$9.36

250d High

$32.60

Next resistance

+79.3%

to 20d High

ROE

-46.1%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 0.6

Upstream Bio: quick answers

What stage is Upstream Bio in?

As of Oct 22, 2026, Upstream Bio (UPB) is in Stage 4, the downtrend phase. It entered Stage 4 on Sep 15, 2026 and is in week 6. What the four stages mean

Is Upstream Bio in an uptrend?

No. Upstream Bio is in a Stage 4 downtrend. It trades 70.4% below its 200-day average, which is falling.

How far is Upstream Bio from its 52-week high?

Upstream Bio closed at $2.99 on Oct 22, 2026, 90.8% below its 52-week high of $32.60. Its 52-week low is $2.76.

How has Upstream Bio performed over the past year?

As of Oct 22, 2026, Upstream Bio is down 86.6% over the past year and down 89.0% so far in 2026.

Which sector and industry is Upstream Bio in?

Upstream Bio is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.